Drug Profile
Bevacizumab biosimilar - BioXpress Therapeutics
Alternative Names: BX 2314; BXT-2316Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer in Switzerland (IV, Infusion)
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer in Switzerland (IV, Infusion)
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Glioblastoma in Switzerland (IV, Infusion)